摘要
目的探讨PS2蛋白、PS2mRNA和P450arom、P450arommRNA在青春期乳房肥大症乳腺组织中的表达及意义。方法应用Western Blo和RT-PCR的方法测定15例青春期乳房肥大症乳腺组织中PS2蛋白、PS2mRNA和P450arom、P450arommRNA的表达情况,并与10例原发性小乳症和15例正常乳腺组织中的PS2蛋白、PS2mRNA和P450arom、P450arommRNA进行对比,探讨PS2和P450arom与青春期乳房肥大症发生、发展的关系,为乳房肥大症的诊断、治疗和预防提供理论依据。结果PS2蛋白、PS2mRNA和P450arom、P450arommRNA的阳性表达率在乳房肥大组、小乳对照组和正常乳腺组间无统计学差异(P＞0.05)。PS2蛋白、PS2mRNA和P450arom、P450arommRNA阳性表达的病例中,青春期乳房肥大症乳腺组织中的平均测定值分别为0.515±0.112、0.424±0.139、0.198±0.060和0.202±0.048;原发性小乳症乳腺组织中的平均测定值分别为0.254±0.097、0.169±0.055、0.139±0.028和0.146±0.034;正常乳腺组织中的平均测定值分别为0.214±0.078、0.163±0.051、0.144±0.072和0.159±0.068。PS2蛋白、PS2mRNA和P450arom、P450arommRNA的阳性表达率在各组间均无统计学差异,但乳房肥大组的PS2蛋白、PS2mRNA和P450arom、P450arommRNA平均测定值高于小乳对照组(P＜0.01/P＜0.01/P＜0.05/P＜0.05),乳房肥大组的PS2蛋白、PS2mRNA和P450arom、P450arommRNA平均测定值高于正常对照组(P＜0.01/P＜0.01/P＜0.05/P＜0.05)。结论青春期乳房肥大症的发生、发展与乳腺组织中PS2蛋白、PS2mRNA和P450arom、P450arommRNA的表达情况有关。
Objective To investigate the expression status of the PS2, PS2mRNA, P450arom, P450arommRNA in breast tissue of pubertal mammary hypertrophy and then explore the possible etiology of pubertal mammary hypertrophy. Methods 15 patients were selected for pubertal mammary hypertrophy group. Breast hypertrophy tissue specimens were collected from the gland excised during reduction mammaplasty. The selection criterion was weight of the excised breast gland greater than 350 g. Patients were excluded if they had any of the following conditions: irregular menstrual cycle; history of pregnancy; hormonal treatment within at least 2 months; nipple discharge from either breast; cyst or fluid and milk concentration in the gland; family history of breast cancer; history of unilateral breast cancer, fibroadenoma or atypical hyperplasia. 10 patients with micromastia were used as a control group. The tissue specimens were obtained during the augmentation mammaplasty. 15 patients with pathologically simple fibroadenoma were used as another control group. The tissue specimens were obtained 3cm away from the fibroadenoma during the tumorectomy. These patients also met the conditions mentioned above. The reduction mammaplasty, augmentation mammaplasty and tumorectomy procedures were performed during the follicular phase of the menstrual cycle. Patient approval of participation in this study was obtained preoperatively. The expression of PS2 , PS2mRNA, P450arom, P450arommRNA was detected by Western Blot and RT-PCR in all the cases above. Results There was no significant difference among the pubertal mammary hypertrophy groups、micromastia groups and normal groups on the expression rates of PS2、PS2mRNA、P450arom、P450arommRNA. But among the positive cases, the expression of PS2、PS2mRNA、P450arom、P450arommRNA within breast tissue were respectively 0.515±0.112. 0.424±0.139. 0.198±0.060. 0.202±0.048 in pubertal mammary hypertrophy group; and 0.254±0.097、0.169±0.055、0.139±0.028、0.146±0.034 in micromastia group, and 0.214±0.078、0.163±0.051、0.144±0.072、0.159±0.068 in normal group. There was significant difference between the pubertal mammary hypertrophy and micromastia groups (P<0.01/ P<0. 01/P <0. 05/P < 0.05) and there was also significant difference between the pubertal mammary hypertrophy and normal groups (P<0.01/ P<0.01/P < 0.05/P <0.05) . Conclusion The expression of PS2, PS2mRNA, P450arom, P450arommRNA in pubertal mammary hypertrophy are significantly higher than in micromastia and in normal mammary glandular tissue. The pubertal mammary hypertrophy may be related to the expression status of PS2, PS2mRNA, P450arom, P450arommRNA within breast tissue.
引文
[1]Peterson OW,Hoyer PE,van Duurs B.Frequency and distribution oof estrogen receptor positive cells in normal,non-lactating human breast tissue.Cancer Res.1987,47:5748-5751.
[2]Leygue ER,Watson PH,Murphy LC.Estrogen receptor variants in normal human mammary tissue.J Natl Cancer Inst,1996,88:284-290.
[3]Jabs AD,Frantz AG,Smith-Vaniz A,et al.Mammary hypertrophy is not associated with increased estrogen receptors.Plast Reconstr Surg,1990,86(1):64-66.
[4]Morimoto T,Komaki K,Mori T,et al.Juvenile gigantomastia:report of a case.Surg Today,1993,23(3):260-264.
[5]Noczynska A,Wasikowa R,Myczkowski T.Hypersensitivity of estrogen receptors as a cause of gigantomasty in two girls.Pol Merkuriusz Lek,2001,11(66):507-509.
[6]秦映芬,沈寒蕾,黄松,等.巨乳症的临床与病理学观察.临床与实验病理学杂志,2004,20(3):292-294.
[7]Baker SB,Burkey BA,Thornton P,et al.Juvenile gigantomastia:presentation of four cases and review of the literature.Ann Plast Surg,2001,46(5):517-525.
[8]孙家明,乔群,戚可名.肥大乳房和小乳房乳腺组织中雌激素受体的表达.中华整形外科杂志,2004,20(6):416-418.
[9]张芾男,滕利,杨锴,等.青春期乳房肥大症乳腺组织中雌激素受体的表达.中国美容医学,2007,(6):6-158.
[10]Masiakowski P,Breathnach R,Bloch J,et al.Cloning of cDNA sequences of hormone regulated genes from the MCF-7 human breastcancer cell line[J].Nucleic Acids Res,1982,10:7895-99.
[11]Martin V,Ribieras S,Rio MC.The estrogen responsive element of the PS2gene is recognized by a methylation sensitive DNA binding protein[J].Biol Chem,1998,379(4-5):409-416.
[12]Polshakov Ⅵ.High-resolution solution structure of human pNR-2/PS2:a single trefoil motif protein[J].J Mol biol,1997,267(2):418-432.
[13]Rio MC,Chambon P.The PS2 gene,mRNA,and protein:a potential marker for human breast cancer. Cancer Cells, 1990,2(8-9):269-274.
[14] Prud'homme JF, Jolivet A, Pichon MF, et al. Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/PS2) obtained by expression in Escherichia coli. Cancer Res, 1990,50(8):2390-2396.
[15] Pallud C, Le Doussal V, Pichon MF, et al. Immunohistochemistry of PS2 in normal human breast and in various histological forms of breast tumours. Histopathology,1993,23(3):249-256.
[16] Ioachim E, Taanou E, Briasoulis E, et al. Clinicopathological study of the expression of hsp27, PS2, cathepsin D and metallothionein in primary invasive breast cancer .Breast, 2003,12(2):111-119.
[17] Predine J,Spyratos F,Prud F,et al.Enzyme linked immunosorbent assay of PS2 in breast cancer,benign tumors,and normal breast tissues [J].Cancer,1992,69(8):2116-2123.
[18] Miyashita S,Hirota M,kYamamoto T.Effect of basic fibroblast growth factor on synthesis/secretion of PS2 protein by human breast cancer cells(MCF-7)[J].Eur J Biochem, 1994,225(3): 1041 -1046.
[19] Rody A,Diallo R,Poremba C , et al.Estrogen receptor alpha and beta, progesterone receptor, PS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncol Rep. 2004 Oct;12(4):695-699.
[20] Foekens JA, Portengen H, Look MP, et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer[J].Br J Cancer, 1994,70:1217-1223.
[21] Thor AD, Koerner FC, Edgerton SM, et al. PS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival[J].Breast Cancer Res Treat,1992,21:l 11-116.
[22] Besse G, Kwiatkowski F, Gaillard G,et al. PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study [J].BuIl Cancer, 1994,81:289-96.
[23] Kawabate K, Watanabe K, Ozaki S. Expression of PS2-protein in breast cancer[J].Rinsho Byori,1996,44:647-52.
[24] Soubeyram I, Quenel N, Coindre JM, et al. PS2 protein:a marker improving prediction of response to neoadjuvant tamoxifen in postmenopausal breast cancer patients[J].BrJCancer, 1996,74:1120-1125.
[25] Thompson AM,Elton RA,et al.PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer.Br J Cancer, 1998,77:492-496.
[26] Biswas DK, Averboukh L, Sheng S, et al. Classification of breast cancer cells on the basis of a functional assay for estrogen receptor [J].Mol Med,1998,4:454-67.
[27] Chan CM, Dowsett M, A novel estrogen receptor variant Mrna lacking exons 4 to 6 in breast carcinoma[J].JSteroid Biochem Mol Biol,1997,62:419-30.
[28] Fiorelli G, Picariello L, M artineti V, et al. Estrogen synthesis in human colon cancer epithelial cells [J]. SteroidBiochem MolBiol, 1999, 71(526): 223- 230.
[29] Simpson ER. A romatase: biologic relevance of tissue specific expression [J]. Sem in Reprod Med, 2004, 22(1): 11- 23.
[30] Hinshelwood MM, Mendelson CR, Tissue-specific expression of the human CYP19 (aromatase) gene in ovary and adipose tissue of transgenic mice. J Steroid Biochem Mol Biol,2001,79(1-5):193-201.
[31] Simpson ER, M ichael MD, Agarwal VR, et al.Cytochromes P450 11: expression of the CYP19(aromatase) gene: an unusual case of alternative promoter usage [J]. FASEB J, 1997,11(1): 29-36.
[32] Simpson ER, Clyne C, Rubin G, et al. A romatase2a brief overview [J. Annu Rev Physiol, 2002, 64(6): 93- 127.
[33] Luis SN,Kazuto T,Khaled MZ,et al.Prostaglandin E2 stimulates aromatase expression in endometriosis derived stromal cells[J].JClin Endocrinol Metab,1997,82 (2):600-606.
[34] Brueggemeier RW, Richards JA, Petrel TA.Aromatase and cyslooxygenases : enzymes in breast cancer[J].Steroid Biochem Mol Biol,2003,86(3-5):501-507.
[35] Bolufel P,Bicart E,L luch A, et al. A romatase activity and estradiol in human breast cancer : its relationship to estradiol and epidermal grow th factor receptors and to tumor2node2metastasis staging[J]. J Clin Oncol, 1992, 10(3): 438-446.
[36] M iyoshi Y, Ando A, Shiba E, et al. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers[J]. Int J Cancer, 2001, 94(5): 685~689.
[37] Agarwal VR, Bulun SE, LeitchM,et al. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients[J].J Clin Endocrinol Metab,1996,81(11):3843-3849.
[38]Bulun SE,Sebastian S,Takayama K,et al.The human CYP19(aromatase P450) gene:update on physiologic roles and genom ic organization of promoters[J].SteroidBiochem MolBiol,2003,86(325):219-224.
[39]Rubin GL,Duong JH,Clyne CD,et al.L igands for the peroxisomal proliferator2activated receptor2Xand the retinoid X receptor inhibit aromatase cytochrome P450(CYP19) expression mediated by promoter in human breast adipose[J.Endocrinology,2002,143(8):2863-2871.
[40]Regnault P,Daniel RK.Aesthetic plastic surgery.Boston:little,Brown,1984:500-501.
[41]徐兵河.乳腺癌[M].北京:北京大学医学出版社,2005:191-192.
[1] Masiakowski P, Breathnach R, Bloch J, et al. Cloning of cDNA sequences of hormone regulated genes from the MCF-7 human breastcancer cell line[J]. Nucleic Acids Res, 1982,10:7895-99.
[2]DetreS,KingN,SalterJ,etal.Immunohistochemical and biochemical analysis of the oestrogen regulated protein PS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer[J].Jclin Pathol,1994,47:240.
[3] Martin V,Ribieras S,Rio MC.The estrogen responsive element of the PS2gcne is recognized by a methylation sensitive DNA binding protein[J].Biol Chem,1998,379(4-5):409-416.
[4] Polshakov VI.High-resolution solution structure of human pNR-2/PS2:a single trefoil motif protein[J].J Mol biol,1997,267(2):418-432.
[5]Podolsky DK, Lynch-Devaney K, Stow JL , et al.Identification of human intestinal trefoil factor , glober cell-specific of a peptide targeted for apical ecretionlJ Biol Chern , 1993 , 268 (9):6694—6702.
[6] Hanby AM, Poulsom R, Singh S,et al. Spasmolytic polypeptide is a major antral peptide:distribution of the trefoil peptides human spasmolytic polypeptide and PS2 in the stomach.Gastroenterology.1993 Oct;105(4):1110-1116.
[7]Koshiyama M, Yoshida M, Konishi M,et al. Expression of PS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status.Int J Cancer. 1997 Jun 20;74(3):237-44.
[8]Langer G, Jagln W, Behrens-Baumann W,et al. Secretory peptides TFF1 and TFF3 synthesized in human conjunctival goblet cells.Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2220-2224.
[9]Rio MC, Chenaral MP, Wolf C,et al. Induction of PS2 and hSP genes as markers of mucosal ulceration of the digestive tract.Gastroenterology. 1991 Feb;100(2):375-9.
[10|Henry JA, Piggott NH, Malick UK,et al. pNR-2/PS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.Br J Cancer. 1991 Apr;63(4):615-22.
[11]Ioachim E,Taanou E,Briasoulis E,et al.Clinicopathological study of the expression of hsp27,PS2,cathepsin D and metallothionein in primary invasive breast cancer.Breast,2003,12(2):111-119.
[12]Thompson AM,Elton RA,et al.PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer.Br J Cancer,1998,77:492-496.
[13]程家骧,林汉良,梁小曼,等·乳腺浸润性癌PS2蛋白的表达及其与预后的关系[J].中华病理学杂志,1997,12:231.
[14]Koshiyama M,Yoshida M,Konishi M.PS2protein in endometrial carcinomas:correlation with clinicopathology features and sex steroid receptor status[J].Int J Cancer,1997,74:237-244.
[15]Wang TC,Cardiff RD,Zukerberg L,et al.Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.Nature,1994,369(6482):669-671.
[16]Miyashita S,Hirota M,kYamamoto T.Effect of basic fibroblast growth factor on synthesis/secretion of PS2 protein by human breast cancer cells(MCF-7)[J].Eur J Biochem,1994,225(3):1041-1046.
[17]Lefebvre O,Cheenard MP,Masson R.Gastric mucosa abnormalities and tumourigenesis in mice lacking the PS2 trefoil proteir[J].Science,1996,274:259-262.
[18]Poulsom R,Wright NA.Trefoil peptides:a newly recognized family of epithelial mucin-associated molecules[J].Am J Physlo,1993,265(2pt 1):205-213.
[19]Taupin DR,Cook GA,Yeomans ND.Increased trefoil peptied expression occurs late in the healing phase in a model of gastric ulceration in the rat[J].Gastroenterology,1994,106:A195.
[20]Dignass A,Devaney KL,Lindon H,et al.Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway.J Clin Invest.1994Jul;94(1):376-383.
[21]Rihieras S,Tomasetto C,RioMC,et al.The PS2/TFF1 trefoil factor,from basic research to clinical applications.Biochim Biophys Acta.1998 Aug 19;1378(1):F61-77.
[22]Donoviel DB,Hadjantonakis AK,Ikeda M,et al.Mice lacking both presenilin genes exhibit early embryonic patterning defects.Genes Dev.1999 Nov 1;13(21):2801-2810.
[23]Poulsom R,Chinery R,Sarraf C,et al.Trefoil peptide gene expression in small intestinal Crohn's disease and dietary adaptation.J Clin Gastroenterol.1993;17 Suppl 1:S78-91.
[24]Poulsom R,Wright NA.Trefoil peptides:a newly recognized family of epithelial mucin-associated molecules[J].Am J Physlo,1993,265(2pt1):205-213.
[25] Rio MC, Chambon P. The PS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells, 1990,2(8-9):269-274.
[26]Prud'homme JF, Jolivet A, Pichon MF, et al. Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/PS2) obtained by expression in Escherichia coli. Cancer Res, 1990,50(8):2390-2396.
[27]Pallud C, Le Doussal V, Pichon MF, et al. Immunohistochemistry of PS2 in normal human breast and in various histological forms of breast tumours. Histopathology,1993,23(3):249-256.
[28]Predine J,Spyratos F,Prud F,et al.Enzyme linked immunosorbent assay of PS2 in breast cancer,benign tumors,and normal breast tissues [J].Cancer,1992, 69(8):2116-2123.
[29]Ioachim E, Tsanou E, Briasoulis E, Clinicopathological study of the expression of hsp27,PS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast. 2003 Apr;12(2):111-9
[30]Pujol P, Daures JP, Brouillet JP. et al. Time at surgery durig menstrualcycle and menopause affects PS2 but not cathepsin D levels in breast cancer[J].Br J Cancer, 1999,79:909-14.
[31]Gion M, Mione R, Pappagallo GL, et al. PS2 in breast cancer-alternative or complementary tool of steroid receptor status? Evaluation of 446 cases[J].Br J Cancer,1993,68:374-79.
[32] 王梅,姜斌,薛春燕,等.PS2在乳腺癌组织中的表达及其临床意义.中华癌症杂志,2002,12(4):301-302.
[33] Dittadi R, Biganzoli E, Boracchi P, et al. Impact of steroid receptors, PS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen[J].Int J Biol Markers,1998,13:30-41.
[34]Foekens JA, Portengen H, Look MP, et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer[J].Br J Cancer, 1994,70:1217-1223.
[35]Soubeyram I, Quenel N, Coindre JM, et al. PS2 protein:a marker improving prediction of response to neoadjuvant tamoxifen in postmenopausal breast cancer patients[Jl.BrJCancer,1996,74:1120-1125.
[36]Looi LM, Azura WW, Cheah PL, et al. PS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status .Pathology, 2001, 33(3) :283 .
[37]Corte MD, Tamargo F, Alvarez A,et al. Cytosolic levels of TFF1/PS2 in breast cancer:Their relationship with clinical-pathological parameters and their prognostic significance. Breast Cancer Res Treat, 2006 Mar;96(1):63-72.
[38]Speiser P, Stolzlechner J, Haider K, et al. PS2 protein status fails to be an independent prognostic factor in an average breast cancer population[J].Anticancer Res, 1994; 14:2125-30.
[39]Horiguchi J,Yuichi I, Hiroyuki T. Expression of PS2 estrogen-in-ducible protein in primary breast cancer[J].Oncology,1996,53:12-17.
[40] Besse G, Kwiatkowski F, Gaillard G,et al. PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study [J].Bull Cancer, 1994,81:289-96.
[41]Rody A,Diallo R,Poremba C , et al.Estrogen receptor alpha and beta, progesterone receptor, PS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncol Rep. 2004 Oct;12(4):695-9.
[42]Thor AD, Koerner FC, Edgerton SM, et al. PS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival[J].Breast Cancer Res Treat,1992,21:111-116.
[43]Kawabate K, Watanabe K, Ozaki S. Expression of PS2-protein in breast cancer[J].Rinsho Byori,1996,44:647-52.
[44]Biswas DK, Averboukh L, Sheng S, et al. Classification of breast cancer cells on the basis of a functional assay for estrogen receptor [J].Mol Med,1998,4:454-67.
[45]Chan CM, Dowsett M, A novel estrogen receptor variant Mrna lacking exons 4 to 6 in breast carcinoma[J].JSteroid Biochem Mol Biol,1997,62:419-30.
[46]Machado JC,Carneiro F,Riberiro P.PS2protein expression in gastric carcinoma.An immunohistochemical and immunoradiometric study[J].Eur J Cancer, 1996, 32A:1585-1590.
[1] Fiorelli G, Picariello L, M artineti V, et al. Estrogen synthesis in human colon cancer epithelial cells [J]. SteroidBiochem MolBiol, 1999, 71(526): 223- 230.
[2]Simpson ER. A romatase: biologic relevance of tissue specific expression [J]. Sem in Reprod Med, 2004, 22(1): 11- 23.
[3]Hinshelwood MM, Mendelson CR, Tissue-specific expression of the human CYP19 (aromatase) gene in ovary and adipose tissue of transgenic mice. J Steroid Biochem Mol Biol,2001,79( 1 -5): 193-201.
[4]Simpson ER, M ichael MD, Agarwal VR, et al.Cytochromes P450 11: expression of the CYP19(aromatase) gene: an unusual case of alternative promoter usage [J]. FASEB J, 1997,11(1): 29-36.
[5]Simpson ER, Clyne C, Rubin G, et al. A romatase2a brief overview [J. Annu Rev Physiol,2002, 64(6): 93- 127.
[6]Ying Z,John E N,Renee V,et al.Prostaglandin E2 stimulates aromatase gene expression in human adipose stromal cells through use of an activation protein-1 binding site upstream of promtor I.4[J].Mol Endocrinol,1996,10(11):1350-1357.
[7]Luis SN.Kazuto T,Khaled MZ,et al.Prostaglandin E2 stimulates aromatase expression in endometriosis derived stromal cells[J].JClin Endocrinol Metab,1997,82 (2):600-606.
[8]Brueggemeier RW, Richards JA, Petrel TA.Aromatase and cyslooxygenases : enzymes in breast cancer[J].Steroid Biochem Mol Biol,2003,86(3-5):501-507
[9] Picton HM, Campbell BK, Hunter MGMaintenance of oestradiol production and expression of cytochrome P450 aromatase enzyme mRNA in long-term serum-free cultures of pig granulosa cells.J Reprod Fertil. 1999 Jan;115(1):67-77
[10] Guthrie HD, Barber JA, Leighton JK, et al.Steroidogenic cytochrome P450 enzyme messenger ribonucleic acids and follicular fluid steroids in individual follicles during preovulatory maturation in the pig.Biol Reprod. 1994 Sep;51(3):465-471.
[11] Araki K, Yasui-Furukori N, Fukasawa T, et al.Otani K.Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism.Eur J Clin Pharmacol.2004 Aug;60(6):427-430.
[12]Simpson ER.Genetic mutations resulting in estrogen insufficiency in the male[J].Mol Cell Endocrinol,1998,145(1-2):55-59.
[13]Bolufel P,Bicart E,L luch A,et al.A romatase activity and estradiol in human breast cancer:its relationship to estradiol and epidermal grow th factor receptors and to tumor2node2metastasis staging[J].J Clin Oncol,1992,10(3):438-446.
[14]M iyoshi Y,Ando A,Shiba E,et al.Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradioi levels in postmenopausal breast cancers[J].Int J Cancer,2001,94(5):685-689.
[15]Agarwal VR,Bulun SE,LeitchM,et al.Use of alternative promoters to express the aromatase cytochrome P450(CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients[J].J Clin Endocrinol Metab,1996,81(11):3843-3849.
[16]Bulun SE,Sebastian S,Takayama K,et al.The human CYP19(aromatase P450) gene:update on physiologic roles and genom ic organization of promoters[J].SteroidBiochem MolBiol,2003,86(325):219-224.
[17]Rubin GL,Duong JH,Clyne CD,et al.L igands for the peroxisomal proliferator2activated receptor2Xand the retinoid X receptor inhibit aromatase cytochrome P450(CYP19) expression mediated by promoter in human breast adipose[J.Endocrinology,2002,143(8):2863-2871.
[18]KristensenVN,Kure EH,Erikstein B,et al.Genetic susceptibility and environmental estrogen like compounds[J].Mutation Res,2001,482(122):77282.2
[19]Bulun SE,Takayama K,Suzuki T,et al.Organization of the human aromatase P450(CYP19)gene[Jl.Semin reprod med,2004,22(1):5-9.
[20]Diaz Cruz ES,Shapiro CL,Brueggemeier RW.Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells[J].Clin EndocrinolMetab,2005,90(5):2563-2570.
[21]徐兵河.乳腺癌[M].北京:北京大学医学出版社,2005:191-192.
[22]王佳玉 徐兵河 芳香化酶抑制剂在乳腺癌内分泌治疗中的地位及展望[J].中华肿瘤杂志,2004,26(8):5072508.
[23]Takahashi K,Nagata H,Kitao M,et al.Clinical usefulness of detemination of estradiol level in the menstrual blood for patients with endometriosis.Acta Obstet Gynecal Jpn,1989,41(12):1849-1850.
[24]Noble LS,Simpson ER,Johns A,et al.Aromatase expression in endometrosis.J Clin Endocrinol Metab,1996,81(1):174-179.
[25]Kitawaki J,Noguchi T.Epression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissue butin normal endometrium.Biol Reprod,1997,57(3):514-519.
[26]Zeitoun K,Takayama K,Michael MD,et al.Stimulation of aromatase P450promoter(Ⅱ)activity in endometriosis and its inhibition in endometrium are regulated by competitive biding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element.Mol Endocrinol,1999,13(2):239-253.
[27]Zhao Y,Nichols JE,Bulun SE,et al.Aromatase P450gene expression in human adipose tissue:role of a JAK/STAT pathway in regulation of the adipose-specific promoter.J Biol Chem,1995,270(2):16449-16457.
[28]Noble LS,Takayama K,Putman JM,et al.Prostaglandin E2 stimulates aromatase expression in endometrosis-derived stromal cells.J Clin Endocrinol Metab,1997,82(2):600-606.
[29]周向东,蔡文琴.芳香化酶mRNA在肺癌组织中表达的初步研究.中国肺癌杂志,2000,3(4):269-271.